Sort by:

select Language:

Mejores prácticas para la atención de pacientes con tuberculosis

G. Williams, E. Alarcón, S. Jittimanee et al., (2017)

Guía para países de bajos ingresos. 2 edición

Field Guide for the Management of Drug-Resistant Tuberculosis

A. Piubello, Eds.: The International Union Against Tuberculosis and Lung Disease, (2018)

A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.

Management of Diabetes Mellitus-Tuberculosis – A Guide to the Essential Practice

Lin Yan, Anthony D Harries, Ajay M V Kumar, et al., Eds.: The International Union Against Tuberculosis and Lung Disease, (2018)

This resource provides practical guidance for front line health workers responsible for the diagnosis, management and care of patients with these two diseases. Published in collaboration with the World Diabetes Foundation.

Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income Countries

G. Williams, E. Alarcón, S. Jittimanee et al., Eds.: The International Union Against Tuberculosis and Lung Disease, (2017)

2nd edition. The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide

Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Policy brief

World Health Organization WHO, (2018)

Cryptococcal meningitis is a serious opportunistic infection which is a major cause of morbidity and mortality in people living with HIV with advanced disease, accounting for an estimated 15% of all AIDS-related deaths globally. An estimated 223,100 cases of cryptococcal meningitis result in 181,000 deaths each year among people living with HIV. Cryptococcal disease is rare in children with HIV, even in areas with a high disease burden among adults

World Health Organization. Typhoid vaccines: WHO position paper.

World Health Organization WHO, (2018)

Accessed Sept, 5 2018 Weekly epidemiological record, Relevé épidémiologique hebdomadaire : Vol.93 (2018) No.13

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)

World Health Organization WHO, (2018)

The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked medicines for all patients with MDR-TB.

Medicines Catalog August 2018

Global Drug Facility, Eds.: World Health Organization WHO, Stop TB, (2018)

The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.

API Recommendations for the Management of Typhoid Fever

Rajesh Upadhyay, Milind Y Nadkar, A Muruganathan, (2015)

Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96

331 hits